References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLe phénotype d’Akhenaton ; revue critique entre canons artistiques et expression pathologique.
JEDIDI, Zayd ULg; JEDIDI, Haroun ULg; LAVEAUX, Elisabeth ULg et al

in Revue Médicale de Liège (in press)

Of all the royal families of ancient or modern fame, few are as iconic as the eighteenth dynasty of pharaohs of the New Kingdom of Egypt, whose opulence and deeds we are still familiar to nearly 3,500 ... [more ▼]

Of all the royal families of ancient or modern fame, few are as iconic as the eighteenth dynasty of pharaohs of the New Kingdom of Egypt, whose opulence and deeds we are still familiar to nearly 3,500 years after their time. Tenth pharaoh of this dynasty and father of Tutankhamun, Akhenaten (Amenhotep/Amenhotep IV) still fascinates Egyptologists and history lovers through the many questions surrounding his atypical rule. One of the most striking aspects of the so-called Amarna period concerns the representations of the pharaoh himself, very confusing compared to the traditional iconography of the New Kingdom. These intriguing portraits of Pharaoh raised a whole lot of medical assumptions, more or less substantiated. We review here the main theories developed throughout history. [less ▲]

Detailed reference viewed: 166 (48 ULg)
Full Text
Peer Reviewed
See detailAdvances in diagnosis and management of familial pituitary adenomas
JEDIDI, Haroun ULg; ROSTOMYAN, Lilith; POTORAC, Iulia et al

in International Journal of Endocrine Oncology (in press)

Familial pituitary adenomas accounts for approximately 5-8 % of all pituitary adenomas. Besides the adenomas occurring as part of syndromic entities that bring together several endocrine or other systems ... [more ▼]

Familial pituitary adenomas accounts for approximately 5-8 % of all pituitary adenomas. Besides the adenomas occurring as part of syndromic entities that bring together several endocrine or other systems disorders, 2-3% of the familial pituitary adenomas fit into the familial isolated pituitary adenomas (FIPA) syndrome. 20% of FIPA syndromes have shown mutations in the AIP gene and have distinct clinical characteristics. Recent findings have isolated a new non-AIP FIPA syndrome called X-LAG, resulting from duplication in GPR-101 gene. These new advances in the field of pituitary disease are opening up a new challenging domain to both clinician and researcher. This review will focus on these last findings and their contribution to the diagnosis and the management of familial pituitary adenomas. [less ▲]

Detailed reference viewed: 174 (4 ULg)
Full Text
Peer Reviewed
See detailGenetics of Pituitary Tumor Syndromes
Daly, Adrian ULg; BECKERS, Albert ULg

in Melmed, Shlomo (Ed.) The Pituitary (2017)

Detailed reference viewed: 25 (5 ULg)
Full Text
Peer Reviewed
See detailPaleogenetic study of ancient DNA suggestive of X-Linked acrogigantism
Beckers, Albert ULg; Fernandes, Daniel; Fina, Frederic et al

in Endocrine-Related Cancer (2017)

Detailed reference viewed: 13 (3 ULg)
Full Text
See detailSomatic mosaicism is implicated in the etiology of XLAG syndrome
Rostomyan, Liliya ULg; Daly, Adrian ULg; Yuan, Bo et al

in Abstract book : Symposium "Perspectives in Endocrinology" (2017, January)

Detailed reference viewed: 21 (2 ULg)
Full Text
See detailGenetic predisposition to breast cancer occuring in a male-to-female transsexual patient
Potorac, Iulia ULg; CORMAN, Vinciane ULg; Manto, Florence ULg et al

in Abstract book : Symposium "Perspectives in Endocrinology" (2017, January)

Detailed reference viewed: 34 (1 ULg)
See detailThe road from the adenoma valley through the forest of genetic testing in pituitary adenoma
Beckers, Albert ULg

Scientific conference (2017, January)

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailCabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere, A.; Cortet, C.; Chanson, P. et al

in European Journal of Endocrinology (2017), 176(3), 305-314

OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of ... [more ▼]

OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD. DESIGN: We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals. METHODS: Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers of hypercortisolism and adverse effects were recorded. RESULTS: Twenty-one (40%) of 53 patients who received cabergoline monotherapy had normal urinary free cortisol (UFC) values within 12 months (complete responders), and five of these patients developed corticotropic insufficiency. The fall in UFC was associated with significant reductions in midnight cortisol and plasma ACTH, and with clinical improvement. Compared to other patients, complete responders had similar median baseline UFC (2.0 vs 2.5xULN) and plasma prolactin concentrations but received lower doses of cabergoline (1.5 vs 3.5 mg/week, P < 0.05). During long-term treatment (>12 months), cabergoline was withdrawn in 28% of complete responders because of treatment escape or intolerance. Overall, sustained control of hypercortisolism was obtained in 23% of patients for 32.5 months (19-105). Nine patients on steroidogenesis inhibitors received cabergoline add-on therapy for 19 months (1-240). Hypercortisolism was controlled in 56% of these patients during the first year of treatment with cabergoline at 1.0 mg/week (0.5-3.5). CONCLUSIONS: About 20-25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline. [less ▲]

Detailed reference viewed: 24 (2 ULg)
Full Text
Peer Reviewed
See detailMRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff, J.; Tejedor, I.; Potorac, Iulia ULg et al

in European Journal of Endocrinology (2017), 176(3), 323-328

OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin ... [more ▼]

OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. PATIENTS AND METHODS: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained. RESULTS: In total, 115 patients were included (63 men and 52 women; mean age at diagnosis: 36.3 years). Mean baseline prolactin level was 2224 +/- 6839 ng/mL. No significant increase of tumor volume was observed during the follow-up. Of the 21 patients (18%) who presented asymptomatic hemorrhagic changes of the macroprolactinoma on MRI, 2 had a tumor increase (2 and 7 mm in the largest size). Both were treated by cabergoline (1 mg/week) with normal prolactin levels obtained for 6 and 24 months. For both patients, no further growth was observed on MRI during follow-up at the same dose of cabergoline. CONCLUSION: No significant increase of tumor size was observed in our patients with controlled prolactin levels on DA. MRI follow-up thus appears unnecessary in patients with biologically controlled macroprolactinomas. [less ▲]

Detailed reference viewed: 26 (2 ULg)
Full Text
Peer Reviewed
See detailA multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
Franck, Sanne Elisabeth; Korevaar, Tim; PETROSSIANS, Patrick ULg et al

in European Journal of Endocrinology (2017)

Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and ... [more ▼]

Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and various covariates may affect its dosing and pharmacokinetics. Objective: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues (LA-SSAs). 188) were meta-analysed as a form of external replication to study the predictors of PEGV dosing in addition to LA-SSA, the LAS (n=83) was used to study the predictors of PEGV monotherapy dosing. Multivariable regression models were used to identify predictors of the PEGV dose required to normalize IGF-I levels. <0.001, p=<0.001, p=0.028 and p=0.047, respectively). Taken together, these characteristics predicted the PEGV normalization dose correctly in 63.3% of all patients within a range of +/- 60 mg/week (21.3% within a range of +/- 20 mg/week). For monotherapy, only weight was associated with the PEGV normalization dose (p=<0.001) and predicted this dosage correctly in 77.1% of all patients within a range of +/- 60 mg/week (31.3% within a range of +/- 20 mg/week). Conclusion: In this study, we show that IGF-I levels, weight, height and age can contribute to define the optimal PEGV dose in order to normalize IGF-I levels in addition to LA-SSA. For PEGV monotherapy, only the patient's weight was associated with the IGF-I normalization PEGV dosage. [less ▲]

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailThe role of AIP mutations in pituitary adenomas: 10 years on
Daly, Adrian ULg; BECKERS, Albert ULg

in Endocrine (2016)

Detailed reference viewed: 17 (4 ULg)
See detailScreening for genetic causes of GH hypersecretion
Rostomyan, Liliya ULg; Beckers, Albert ULg

Conference (2016, November)

Detailed reference viewed: 21 (3 ULg)
See detailThe history of XLAG syndrome (2015)
Beckers, Albert ULg

Scientific conference (2016, November)

Detailed reference viewed: 27 (1 ULg)
See detailApplying new developments in the genetic understanding of inherited pituitary adenoma.
Beckers, Albert ULg

Scientific conference (2016, November)

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailUne hypokaliémie à Liège
VALDES SOCIN, Hernan Gonzalo ULg; EMONTS, Patrick ULg; HAMOIR, Etienne ULg et al

Conference (2016, October 15)

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULg; Lancellotti, Patrizio ULg; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 18 (4 ULg)
Full Text
See detailFaut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l'hypersécrétion est contrôlée médicalement ?
Eroukhmanoff, J; Tejedor, I; Potorac, Iulia ULg et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 14 (1 ULg)
Full Text
See detailFrom guidelines to real daily practice : prolactinoma in pregnancy
VROONEN, Laurent ULg; Potorac, Iulia ULg; D'Andréa, S et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 11 (1 ULg)
Full Text
See detailA new clinical presentation of a non-so-rare disease, the Di George syndrome
VROONEN, Laurent ULg; D'Andrea, S; Tome, M et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 17 (2 ULg)